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The usefulness of serum CYFRA 21-1 (cytokeratin-19 fragments) in monitoring the recurrence of breast cancer and in evaluating
therapeutic effects was studied retrospectively. The sera from 173 patients with primary breast cancer or recurrent disease were
measured for CYFRA 21-1, carcinoembryonic antigen (CEA), and carbohydrate antigen 15-3 (CA 15-3) levels. The positive rates of
serum CYFRA 21-1 for stage IV (n¼12) or recurrent disease (n¼26) were 83.3 and 84.6%, respectively, while those of serum CEA
were 41.7 and 26.9%, and those of serum CA 15-3 were 83.3 and 34.6%. The elevated preoperative levels of serum CYFRA 21-1
decreased to normal levels after curative operation, whereas the levels remained abnormally high after noncurative operation. There
was a significantly high frequency of recurrence in patients with elevated levels of serum CYFRA 21-1 preoperatively compared to
those with normal levels of the marker preoperatively. The serum CYFRA 21-1 levels were well correlated with response to
chemotherapy. The positive rate of serum CYFRA 21-1 alone was higher than that of an assay combining CEA with CA 15-3, in both
primary and recurrent cases (28.8 vs 18.8 and 84.6 vs 46.2%, respectively). These observations suggest that serum CYFRA 21-1 may
be a reliable marker of recurrence or therapeutic efficacy.
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The clinical usefulness of serum tumour markers for breast cancer
surveillance has not yet been established. Indeed, until sufficient
data on this subject are obtained, the American Society of Clinical
Oncology (ASCO) recommends against the routine use of even
well-known antigens such as carcinoembryonic antigen (CEA) and
carbohydrate antigen 15-3 (CA 15-3) after primary treatment or in
monitoring responses to treatment (American Society of Clinical
Oncology, 2001). For economic reasons, and to minimise radiation
exposure, it is not possible to carry out the imaging studies, such
as chest and abdominal computed tomography (CT) and bone
scintigraphy, for follow-up and evaluation of therapeutic effect
every 1–3 months. Therefore, it is clearly a worthwhile goal to find
a reliable serum tumour marker with high sensitivity and high
specificity for breast cancer. We previously reported that the
positive rates of serum CYFRA 21-1, which reacts specifically with
cytokeratin-19 fragments, in patients with stage IV or recurrent
breast cancer were as high as those for CA 15-3 and superior to
those for CEA. We also previously demonstrated that serum
CYFRA 21-1 titre had prognostic predictive value in patients with
breast cancer (Nakata et al, 2000). In this study, we measured
serum CYFRA 21-1 titres prior to and after treatment in patients
with breast cancer to observe the potential impact of the use of
serum CYFRA 21-1 in monitoring for recurrence and in evaluating
therapeutic efficacy.
PATIENTS AND METHODS
Patients
The Department of Surgical Oncology of Osaka City University
Graduate School of Medicine first began to use a combination
assay of serum CYFRA 21-1, CEA, and CA 15-3 for diagnosis and
follow-up of patients with breast cancer in January 1999. Between
January 1999 and May 2003, a total of 260 patients were treated for
breast cancer at Osaka City University Hospital, but in 87 (33.5%)
of these cases serum CYFRA 21-1 titres were not measured because
the patients’ doctors were not yet familiar with the combination
assay system. These 87 cases were excluded from this analysis,
leaving 173 patients in whom breast cancer was retrospectively
investigated in the present study. Among these 173 patients, 119
were patients with primary tumours (untreated tumours) in whom
sera were obtained from within 2 weeks prior to resection and at
every 3–6 months after resection according to our follow-up
system using the serum tumour markers CYFRA 21-1, CEA, and
CA 15-3. These 119 patients also underwent routine imaging
studies, including chest X-ray, abdominal ultrasonography/CT,
and bone scintigraphy, every 6–12 months as part of our follow-up
system. Among these 119 patients (median follow-up time after
operation: 25.2 months; range: 3–54 months), 13 (10.9%)
developed recurrent disease, and seven patients with high
preoperative levels of serum CYFRA 21-1 happened to be
measured in the early period of 7–14 days postoperation. In the
remaining 54 patients (41 with primary breast cancer and, as in the
fully assayed patients, 13 with recurrent cancer), sera were
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lobtained only once due to the doctors’ unfamiliarity with the
combination assay system.
The Union Internationale Contre le Cancer (UICC) stages of the
160 patients with primary breast cancer were as follows: stage 0
(n¼3), stage I (n¼46), stage II (n¼62), stage III (n¼37), and
stage IV (n¼12) (Table 1). The staging was based on the complete
pathological findings and imaging studies for each patient. As
described above, the total number of recurrent cases was 26,
among which 13 patients were measured for serum CYFRA 21-1
serially and 13 patients were assessed only once. In 14 patients, a
change in serum CYFRA 21-1 levels was observed during
chemotherapy. Among them, four patients were treated neoadju-
vantly for primary tumours and distant metastases (lung (n¼2),
liver (n¼1), and bone (n¼1)). The other 10 patients were treated
for recurrent metastases (bone (n¼3), boneþliver (n¼3), lung
(n¼2), lungþbone (n¼1), and lymph node (n¼1)). All lesions
except bone metastases were measurable by CT or ultrasonogra-
phy, and bony lesions were evaluable by bone scintigraphy.
Objective responses were classified according to World Health
Organisation criteria (World Health Organization, 1979).
Measurement of tumour markers
Serum CYFRA 21-1 was measured by a solid-phase immunoradio-
metric assay based on the two-site sandwich method using a
CYFRA 21-1 kit (CIS Biointernational, Gif Yvette, France) (Sarwar
et al, 1994). The measurement of serum CEA was completed in a
counting immunoassay. Serum CA 15-3 was measured by a two-
step sandwich immunoradiometric assay. The cutoff values of
CYFRA 21-1, CEA, and CA 15-3 recommended by the manufac-
turers were 2.0ngml
 1, 6.5ngml
 1, and 30Uml
 1, respectively.
Measurement of estrogen receptor (ER) and progesterone
receptor (PgR)
ER status and PgR status were determined by an enzyme-linked
immunoassay, and tumours with more than 5fmolmg
 1 protein
were considered to be positive.
Statistical analysis
Statistical analysis was performed using nonparametric methods.
The Kruskal–Wallis one-way analysis was used for multiple
comparison of the UICC staging groups 0–IV. The Mann–
Whitney U-test was used for comparisons between pairs of
independent groups divided according to UICC staging, ER status,
and PgR status. The w
2 test (Fisher’s exact method) was used to
compare between variables. P-values o0.05 were considered to be
statistically significant.
RESULTS
Serum CYFRA 21-1 titre according to ER and PgR status
The serum CYFRA 21-1 levels of the 87 ER-positive tumours were
not different from those of the 68 ER-negative tumours (median
values: 1.3 vs 1.45ngml
 1, respectively; P¼0.0679). The serum
CYFRA 21-1 levels of the 77 PgR-positive tumours were not
different from those of the 78 PgR-negative tumours (median
values: 1.4 vs 1.4ngml
 1, respectively; P¼0.6762).
Serum tumour marker level in each stage for primary
breast cancer
The serum CYFRA 21-1, CEA, and CA 15-3 titres of all 160 primary
cases are shown in Table 1. The serum CYFRA 21-1 and CA 15-3
levels were significantly different among stages 0–IV (the
Kruskal–Wallis one-way analysis; both, Po0.0001), although the
serum CEA levels were not. Table 1 demonstrates the difference
between the serum levels of the two groups according to UICC
staging in each tumour marker examined based on the results of
the Mann–Whitney U-test. The serum CEA levels were not
significantly different between any two groups. The serum CYFRA
21-1 and CA 15-3 levels were significantly different between all
pairs of groups except 0 vs I–IV, although the P-values for CA 15-3
were a little smaller than those for CYFRA 21-1.
Figure 1 compares the positive rates of serum CYFRA 21-1, CEA,
and CA 15-3 for each stage grouping. No tumour marker was
elevated for stage 0. Among these three markers, CYFRA 21-1 had
the highest rate of positivity in stages I–IV. At stage IV, 10 of 12
patients (83.3%) showed elevated levels of both serum CYFRA 21-1
and CA 15-3.
Serum tumour marker level for recurrent breast cancer
Among the 26 recurrent cases, 84.6% (22 of 26) were positive for
serum CYFRA 21-1, whereas 26.9% (six of 26) and 34.6% (nine of
26) were positive for serum CEA and CA 15-3, respectively
(Figure 2). When the w
2 test was used to examine the rate of
positivity for each of the three tumour markers in the sera of
patients with recurrence, significant differences between CYFRA
21-1 and CEA (Po0.0001) and between CYFRA 21-1 and CA 15-3
Table 1 Serum CYFRA 21-1, CEA, and CA 15-3 titres of 160 patients
with primary breast cancer according to stage
Variables
CYFRA 21-1
(ngml
 1)
CEA
(ngml
 1) CA 15-3 (Uml
 1)
Cutoff value 2.0 6.5 30
UICC staging Median (range) Median (range) Median (range)
0( n¼3) 0.8 (0.2–1.8) 1.4 (1.0–3.6) 11.3 (6.8–12.3)
I( n¼46) 1.3 (0.3–3.0) 2.8 (0.8–9.2) 12.6 (6.5–30.8)
II (n¼62) 1.4 (0.5–6.2) 3.0 (0.9–29.3) 16.2 (5.7–141)
III (n¼37) 1.3 (0.5–23) 2.4 (0.6–48.3) 15.9 (5.4–165)
IV (n¼12) 4.4 (1.2–122) 4.7 (1.1–24.7) 76.3 (14.2–4470)
Kruskal–Wallis test Po0.0001 P¼0.1285 Po0.0001
Mann–Whitney U-test P-value P-value P-value
Stage 0 vs I–IV 0.2568 0.1550 0.0691
Stage 0–I vs II–IV 0.0046 0.0808 0.0001
Stage 0–II vs III–IV 0.0003 0.5038 0.0001
Stage 0–III vs IV o0.0001 0.0676 o0.0001
CEA¼carcinoembryonic antigen; CA¼carbohydrate antigen. UICC¼Union Inter-
nationale Contre le Cancer.
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Figure 1 Comparison of the positive rates of serum CYFRA 21-1 (solid
bar), CEA (open bar), and CA 15-3 (striped bar) at each stage.
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l(Po0.0003) were observed. However, there was no difference
between CEA and CA 15-3 (P¼0.3803).
Changes in serum CYFRA 21-1 levels by resection
The sera from 119 patients with primary tumours were measured
pre- and postoperatively. All 84 patients with negative preoperative
serum CYFRA 21-1 titres had normal levels postoperatively.
However, among the five such patients who developed a later
recurrence, four showed elevated levels of serum CYFRA 21-1. One
of these patients, who had an ipsilateral recurrence after breast
conservation therapy, had a normal serum CYFRA 21-1 titre
(Figure 3). Among the 35 patients with elevated levels of serum
CYFRA 21-1 preoperatively, 29 (82.9%) showed a decrement to
within the normal range postoperatively. Among these 29 patients,
six (20.7%) developed recurrent tumours by 11–35 months
postoperatively and all showed elevated levels of serum CYFRA
21-1. Of the six patients in whom the serum CYFRA 21-1 levels
continued to be elevated postoperatively, three underwent non-
curative operation for lung, liver, or bone metastases; two
developed bony recurrences at 12 and 20 months after operation;
and the sixth patient has so far shown no evidence of recurrence
after curative operation (Figure 4).
Among the 13 recurrent patients whose serum CYFRA 21-1 was
monitored serially, two patients showed elevated serum CYFRA
21-1 titres before the detection of metastatic lesions by imaging
studies. Both of these patients developed liver metastases and
showed elevated levels of CYFRA 21-1 at 3 or 4 months,
respectively, before the detection of tumours by CT scan. In the
other 11 patients, the dates of tumour detection by imaging studies
were almost identical to the dates of detection by elevation of
serum CYFRA 21-1. The reason for this may have been related to
our follow-up system, in which the measurement of tumour
markers and imaging studies were simultaneously ordered.
Another possible reason may have been that, in all patients,
imaging studies were immediately performed whenever the serum
CYFRA 21-1 was found to be elevated.
The sera from seven patients with elevated serum CYFRA 21-1
levels (median: 4.5ngml
 1; range: 2.3–11ngml
 1) preoperatively
were measured within 2 weeks after operation. All the serum
CYFRA 21-1 titres decreased to within the normal range during
this period (Figure 5). These data demonstrate how quickly the
marker decreased in the sera of these patients.
Relation between serum CYFRA 21-1 levels and recurrence
Among the 119 primary breast cancer patients with pre- and
postoperative serum CYFRA 21-1 data, 116 patients underwent
potentially curative operation. These data were analysed to
examine the association between serum CYFRA 21-1 level and
disease recurrence. As shown in Table 2, the patients in whom
serum CYFRA 21-1 levels were elevated both pre- and post-
operatively had the greatest frequency of recurrence. In patients in
whom the serum CYFRA 21-1 levels were elevated preoperatively
and normal postoperatively, the frequency of recurrence was
CYFRA 21-1
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3
CA 15-3
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Figure 2 Distribution of patients with elevated levels of serum CYFRA
21-1, CEA, and CA 15-3 in primary and recurrent breast cancer. The
number in each area is the number of patients with elevated levels of
tumour markers.
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Figure 3 Change of serum CYFRA 21-1 titres of patients within normal
levels at preoperation. The recurrent site is demonstrated for each case,
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Figure 4 Changes in serum CYFRA 21-1 titres of patients with elevated
levels at preoperation. Residual sites are within parentheses. A recurrent
site is demonstrated for each case, and the postoperation time until
recurrence is shown within parentheses. The open circle indicates a patient
with an elevated level of serum CYFRA 21-1 at postoperation, who
nevertheless has shown no evidence of relapse.
10
9
8
7
6
5
4
3
2
1
CYFRA 21-1 (ng ml
−1 )
Pre 1 2 3 5 6 7 8 9 1 01 11 21 31 41 5
11
Days after curative operation
4
Figure 5 The decrement of serum CYFRA 21-1 titre after curative
operation.
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21-1 preoperatively developed recurrences. The frequency of
recurrence in patients with elevated levels of serum CYFRA 21-1
preoperatively was significantly higher than that in patients with
preoperatively normal levels of the marker (P¼0.007).
Changes in serum CYFRA 21-1 levels after chemotherapy
Figure 6 demonstrates the changes in serum CYFRA 21-1
levels before and after chemotherapy. These 14 patients were
administered intensive chemotherapeutic regimens, such as CAF
(cyclophosphamideþadriamycinþ5-fluorouracil), FEC (5-fluoro-
uracilþepirubicinþcyclophosphamide), or taxane with or with-
out herceptin. The serum CYFRA 21-1 levels in five of seven
patients with postoperative recurrence decreased to within the
normal range after chemotherapy, and those of the other two
patients with extremely high levels (175 and 644ngml
 1) prior to
chemotherapy decreased to approximately 3 and 10% of the
prechemotherapy levels after chemotherapy, respectively. In the
four patients with stable disease, chemotherapy reduced the serum
CYFRA 21-1 levels to approximately 20–90% of the preche-
motherapy levels. In the three patients with progressive disease,
the serum CYFRA 21-1 levels were increased by 150–400%
following chemotherapy.
Combination assay of tumour markers for breast cancer
Figure 2 demonstrates the positive case number for each tumour
marker. Among the 160 patients with primary tumours, 104 (65%)
showed normal serum levels of all tumour markers and 46 (28.8%)
had elevated CYFRA 21-1 levels. Also among the primary cases, 26,
six, and two patients showed elevated levels of serum CYFRA
alone, CEA alone, and CA 15-3 alone, respectively. The rates of
positivity for CYFRA 21-1, CEA, and CA 15-3 among the 160
primary tumour cases were 28.8, 12.5, and 12.5%, respectively. The
rate of positivity for all three markers in the combined assay was
35%; CYFRA 21-1 combined with CEA was 33.8%; CYFRA 21-1
with CA 15-3 was 31.3%; and CEA with CA 15-3 was 18.8% among
these 160 patients. Among the 26 patients with recurrent tumours,
22 (84.6%) had elevated CYFRA 21-1 levels. Three of the 26
recurrent patients (11.5%) showed normal serum levels of all
tumour markers. These marker-negative tumours occurred in the
lung, the axillary lymph node, or the ipsilateral breast, respectively.
Among recurrent cases, 11, 0, and one patients showed elevated
levels of serum CYFRA alone, CEA alone, and CA 15-3 alone,
respectively. The positive rates of CYFRA 21-1, CEA, and CA 15-3
for recurrent tumours were 84.6, 23.1, and 34.6%, respectively. In
recurrent cases, the positive rate of the combined assay using all
three markers was 88.5%; CYFRA 21-1 combined with CEA was
84.6%; CYFRA 21-1 with CA 15-3 was 88.5%; and CEA with CA 15-
3 was 46%.
DISCUSSION
It has been well demonstrated that breast cancer cells express
fragments of cytokeratin-19 (Moll et al, 1982; Brotheric et al, 1998;
Sheard et al, 2002), which is one of the various kinds of
cytokeratins comprising the intermediate filaments of the cytos-
keleton (Moll et al, 1982). Serum fragments of cytokeratin-19 can
be detected using anti-CYFRA 21-1 antibody (Pujol et al, 1993).
Most of the epitopes that are detectable by clinically useful tumour
markers such as CEA, CA 15-3, CA 19-9, and alpha-fetoprotein are
glycoproteins shed from the cell surface. CYFRA 21-1 is unique in
that its epitope is a polypeptide, which is most likely released
following cell death (Stieber et al, 1993; Sheard et al, 2002).
Elevated levels of serum CYRFA 21-1 titres have been observed in
various malignancies, especially in lung cancer (Molina et al,
1994). Healthy individuals with an abnormal level of serum CYFRA
21-1 are quite rare (Molina et al, 1994; Nakata et al, 1996;
Giovanella et al, 2002). Patients with nonmalignant disease also
showed almost no elevation of serum CYFRA 21-1, except in cases
of cirrhosis, renal failure, or infectious lung disease. In previous
studies, 20–30% of patients with one of these three benign diseases
showed elevated levels of serum CYRFA 21-1 (Molina et al, 1994;
Nakata et al, 1996). However, little is known about this tumour
marker for breast cancer (Molina et al, 1994; Nakata et al, 2000;
Giovanella et al, 2002; Rodriguez et al, 2002).
Table 2 Comparison of frequency of disease recurrence after potentially curative operation according to pre- and postoperative levels of serum CYFRA
21-1
Serum CYFRA 21-1 (ngml
 1) Number of patients
Group Preoperation Postoperation Recurrence No recurrence Total
A o2 o2 5 (6.0%) 79 84
B 42.1 o2 6 (20.7%) 23 29
C 42.1 42.1 2 (66.6%) 1 3
According to serum CYFRA 21-1 levels at pre- and postoperation, the patients were divided into groups A, B, and C. Frequencies of recurrences were different between A and B
(P¼0.0312), A and C (P¼0.0162), and A and B+C (P¼0.007), but not B and C (P¼0.1468), examined by w
2 test (Fisher’s exact method).
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Figure 6 Change in serum CYFRA 21-1 titres after chemotherapy.
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or recurrent disease, the positive rate of serum CYFRA 21-1 was as
high as that of CA 15-3 and superior to that of CEA (Nakata et al,
2000). In this study, we measured serum CYFRA 21-1 in a new
series of patients, and the results for primary breast cancer were
the same, except that the positive rate of serum CYFRA 21-1 for
recurrent disease was higher than that of serum CA 15-3 (Figures 1
and 2). Rodriguez et al (2002) examined the serum CYFRA 21-1,
CEA, and CA 15-3 titres in their 40 patients with metastatic breast
cancers and found that CYFRA 21-1 was a sensitive tumour marker
for breast cancer when compared with CEA or CA 15-3, supporting
our results. However, contrary to our results, Giovanella et al
(2002) reported that serum CYFRA 21-1 was less accurate for the
evaluation of primary and recurrent breast cancer than serum CA
15-3. The low diagnostic value of CYFRA 21-1 in breast cancer
reported by Giovanella et al should be due to their higher serum
CYFRA 21-1 cutoff value (3.3ngml
 1) compared to our cutoff
value (2.0ngml
 1), although both studies used the same CYFRA
21-1 kit (CIS Biointernational). Our cutoff value was decided by
the manufacturer’s recommendation, while Giovanella et al used
the cutoff value originally selected for lung cancer and benign lung
diseases. Giovanella et al described that they could not employ a
lower cutoff in a breast disease setting, because 5% of the healthy
individuals in their series showed a high level above 3.3ngml
 1.
In our study, the serum marker levels among each stage were
examined by nonparametric analyses, and CYFRA 21-1 and CA 15-
3 were correlated significantly with stage, although CEA was not
(Table 1). However, as described in our previous report (Nakata
et al, 2000) and as shown in this report, the measurement of serum
CYFRA 21-1 cannot be a potential screening test due to the low
positive rate for early breast cancer. We also demonstrated in a
previous report (Nakata et al, 2000) that serum CYFRA 21-1 has
not only a high positive rate for breast cancer but also high
specificity for breast cancer, that is, 22 patients with benign
mammary disease did not show elevated levels of serum CYFRA
21-1. Molina et al (1994) also reported that only 4% (one of 25) of
patients with benign mammary disease had elevated levels of
serum CYFRA 21-1.
The time course of serum CYFRA 21-1 titre during treatment
has not been investigated previously. We observed 119 patients
with primary tumour at pre- and postoperation. We surveyed these
patients and found that 13 of them had had a recurrent tumour.
Among the 35 patients with elevated levels of serum CYFRA 21-1 at
preoperation, only six patients had abnormal levels of this tumour
marker at postoperation. Among the six cases, the high levels in
three cases were attributable to residual tumours, while the high
levels in two cases were probably due to micrometastasis (Figure 4).
These results suggest that serum CYFRA 21-1 may be a good
marker for surgical curability. Moreover, we found that the high
serum titre of CYFRA 21-1 at preoperation decreased to a normal
level within 2 weeks after curative operation (Figure 5). All but one
of the patients who developed recurrent disease showed elevated
levels of CYFRA 21-1, and the one exception had an ipsilateral
recurrence after breast conservation therapy (Figures 3 and 4).
These results suggest that serum CYFRA 21-1 might be a reliable
marker of recurrent disease. Among the 84 patients with normal
levels of serum CYFRA 21-1 preoperatively, five developed
recurrences and four of these demonstrated elevated levels of this
tumour marker. This indicates the potential usefulness of the
marker for monitoring disease relapse, even in cases with normal
levels of serum CYFRA 21-1 at preoperation. Moreover, the
preoperative abnormal levels of CYFRA 21-1 were significantly
related to higher incidence of the disease relapse (Table 2).
The leading time of a tumour marker elevation before
manifestation of relapse by imaging studies is an important
subject. However, our retrospective study demonstrated only two
anecdotal cases in which the leading times of serum CYFRA 21-1
were 3–4 months. To investigate the leading time, a prospective
study may be required, in that serum CYFRA 21-1 should be
measured monthly.
The chemotherapeutic effects of CYFRA 21-1 correlated well
with the changes in serum levels of CYFRA 21-1 between pre- and
postchemotherapy (Figure 6). Partial response efficacy may be
assessed by changes in serum CYFRA 21-1 when the elevated titre
decreases to 10% or less of the preoperative value, or when the
normal range is reached at postchemotherapy.
We observed that the positive rates of serum CYFRA 21-1 alone
in primary and recurrent cases were superior to those of the assay
combining CEA with CA 15-3. The assays combining CYFRA 21-1
with CEA or CA 15-3 increased the positive rate modestly,
increased the positive rate by 5 or 2.5% in primary cases, and 0 or
3.9% in recurrent cases, respectively (Figure 2). These findings
indicated that serum CYFRA 21-1 may be useful even in a single
assay, when a combination assay using two or more tumour
markers is not feasible economically.
In conclusion, the measurement of serum CYFRA 21-1 may be
useful for detecting disease relapse and for assessing surgical and
chemotherapeutic efficacy. However, the patient number in this
study was too small to draw any definitive conclusions. Further
prospective studies using greater numbers of patients are required
before serum CYFRA 21-1 can be recommended for routine
clinical use.
REFERENCES
American Society of Clinical Oncology (2001) 2000 Update of recommen-
dations for the use of tumor markers in breast and colorectal cancer:
clinical practice guideline of the American Society of Clinical Oncology. J
Clin Oncol 19: 1865–1878
Brotheric I, Robson CN, Browell DA, Shenfine J, White MD, Cunliffe WJ,
Shenton BK, Egan M, Webb LA, Lunt LG, Young JR, Higgs MJ (1998)
Cytokeratin expression in breast cancer: phenotypic changes associated
with disease progression. Cytometry 32: 301–308
Giovanella L, Ceriani L, Giardina G, Bardelli D, Tanzi F, Garancini S (2002)
Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for
breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and
carcinoembryonic antigen (CEA). Clin Chem Lab Med 40: 298–303
Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N, Ballesta AM (1994)
Study of a new tumor marker, CYFRA 21-1, in malignant and
nonmalignant diseases. Tumour Biol 15: 318–325
Moll R, Franke WW, Schiller DL (1982) The catalog of human cytokeratins:
patterns of expression in normal epithelia, tumors and cultured cells.
Cell 31: 11–24
Nakata B, Chung YS, Kato Y, Ogawa M, Ogawa Y, Inui A, Maeda K, Sawada
T, Sowa M (1996) Clinical significance of serum CYFRA 21-1 in gastric
cancer. Br J Cancer 73: 1529–1532
Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, Hirakawa K
(2000) Serum CYFRA 21-1 is one of the most reliable tumor markers for
breast carcinoma. Cancer 89: 1285–1290
Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB (1993) Serum
fragment of cytokeratin subunit 19 measured by CYFRA 21-1
immunoradiometric assay as a marker of lung cancer. Cancer Res 53:
61–66
Rodriguez CA, Cruz JJ, Martin T, Gomez A, Olaverri A, Hernandez M
(2002) Letter and author reply: serum CYFRA 21-1 is one of
the most reliable tumor marker for breast carcinoma. Cancer 95:
670–671
Sarwar M, Tomiyoshi K, Inoue T, Fukazawa K, Endo K (1994) CYFRA 21-1
as a tumor marker used in measuring the serum fragment of cyto-
keratin subunit 19 by immunoradiometric assay. Ann Nucl Med 8:
301–306
Serum CYFRA 21-1 in breast cancer
B Nakata et al
877
British Journal of Cancer (2004) 91(5), 873–878 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lSheard MA, Vojtesek B, Simickova M, Valik D (2002) Release of
cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the
extracellular space during apoptosis. J Cell Biochem 85: 670–677
Stieber P, Bodenmuller H, Banauch D, Hasholzner U, Dessauer A,
Ofenloch-Hahnle B, Jaworek D, Fateh-Moghadam A (1993) Cytokeratin
19 fragments: a new marker for non-small-cell lung cancer. Clin Biochem
26: 301–304
World Health Organization (1979) WHO Handbook for Reporting Results of
Cancer Treatment, Offset Publication No 48. Geneva: World Health
Organization
Serum CYFRA 21-1 in breast cancer
B Nakata et al
878
British Journal of Cancer (2004) 91(5), 873–878 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l